Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
08 April 2021 | Story Nonsindiso Qwabe | Photo Sonia SMall
How has COVID-19 further widened the gender inequality gap in the workplace?

This was the central question addressed during the first instalment of a webinar series on Gender and Social Justice hosted by the Unit for Institutional Change and Social Justice at the University of the Free State (UFS). The webinar, which was hosted on the UFS Qwaqwa Campus on 29 March 2021, featured Prof Pearl Sithole, Qwaqwa Campus Vice-Principal: Academic and Research; Advocate Nthabiseng Sepanya-Mogale, Commissioner at the Commission for Gender Equality (CGE); and Tholo Motaung, skills trainer, moderator, and gender activist at the Vaal University of Technology as panellists. 

Prof Sithole said COVID-19 revealed the disparity that still exists between men and women in the workplace. “COVID-19 has been the magnifier. We’ve modernised quite a lot, but we’re still unequal in terms of gender. Why are we not progressing in terms of women moving forward towards equality when there has been so much progressive thinking in the political space, social justice space, as well as in the kind of feminism we have had in academia? Why are we actually not winning the battle of just regarding each other as equals?” 

Women hardest hit by COVID-19 lockdown

Advocate Sepanya-Mogale said the lockdown revealed the gender gap mostly through the significant impact it has had on South African women.

In 2020, 34% of the country’s workforce comprised women – a sharp decline of 9,8% from 43,8% in 2018.
“This decline is alarming and a clear indication of who becomes the first victims, but that is hardly talked about. A lot of women have experienced resistance from industries they had been serving diligently,” she said. She said women were often faced with the burden of integrating their work with increased care responsibilities for their children and sometimes also the elderly as primary caregivers. The double responsibility placed on women continues to re-enforce gender roles in our societies and further pushes away the success of closing the gap on gender equality prospects in our society.

Advocate Sepanya-Mogale said women were the hardest hit in most industries. In the beauty and tourism industry; air transportation; informal trading; and healthcare sector to name a few, women bore the brunt the most. “Women are the biggest employees on all economic levels in South Africa, especially the low-income and unskilled levels,” she said.
She said as the spread of the virus was likely to continue disrupting economic activity, all sectors of society needed to get involved and play their part.

“As disease outbreaks are not likely to disappear in the near future, proactive international action is required to not only save lives but to also protect economic prosperity. Academic institutions are authorities in terms of opening up new discussions, leading new debates, and putting critical issues at the centre of the table. Let us all do what we can so that we empower our people relevantly for the times we’re living in.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept